Gastroenterology

PROSE allows patients to report their symptoms of dysphagia in real-time.

Investigators found fistulizing Crohn’s disease increases the healthcare burden and lengthens the duration of hospital stays in patients with acute kidney injuries.

Volume of waiting list registrations and DDLTs for alcoholic hepatitis exceeded expected trends by a mean of 59.5% in waiting list registrations and 62.0% in DDLTs

Biologic therapies show promising results of clinical remission in patients with Crohn's disease.

It can be challenging to find a suitable donor for fecal microbiota transplantation.

Dr. Aljaras talks about the importance of focusing on diet when examining irritable bowel syndrome.

RBX2660 is a a standardized, stabilized, investigational microbiota-based live therapeutic being studied for the treatment of C difficile infections.

Patients with Crohn's disease often also suffer from kidney dysfunction.

This patient group had higher odds of death and longer lengths of hospital stays.

Patients in both the ADVANCE and MOTIVATE studies achieved enhanced clinical response and endoscopic response.

Hypertension rates were low in both ulcerative colitis and multiple sclerosis patients treated with ozanimod, regardless of concurrent SNRI/SSRI use.

Many of the measures put in place because of COVID-19 have also helped to reduce the rates of C difficile infections.

There was a higher risk of type 2 diabetes in patients with fibrosis stage F4 compared to patients with stage F0 or F2.

Recent studies have shown the majority of potential FMT donors are ultimately rejected.

Recurrent CDI, severe CDI, and the number of stools were linked to lower Cdiff32 scores.

C difficile was found on 45% of shoe soles and 26.2% of private residences.

The 4 factors included baseline body mass index, fibrosis-4 index, albumin level at SVR, and alpha-foetoprotein level at SVR.

Potential donors are denied for a variety of reasons, including high body mass index, underlying chronic illnesses, or the use of antibiotics within 3 months.

There were no episode of gastrointestinal bleeding, transfusion of packed red blood cells, or octreotide infusions observed.

The most severe outcomes occurred in patients with a history of unhealthy alcohol use.

Gastrointestinal symptoms were significantly linked to severe symptoms of depression and anxiety.

Serious infections occurred in less than 2% of patients treated with the medication during the duration of the 52-week trial.

Just 7% of patients in the BPA group suffered a recurrent CDI episode within 14-56 days of initiating treatment.

Taste scores were significantly correlated with depression scores for both patients with irritable bowel syndrome and functional constipation.

The ongoing PIANO registry is designed to keep real time data on the outcomes of pregnant patients with IBD.